- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05214625
Questionnaire Study Concerning Artificial Intelligence
Questionnaire Study Concerning Artificial Intelligence and Its Application in (Gastrointestinal) Healthcare - Patients' and Physicians' Perspectives
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
In recent years, important developments have been made in the field of artificial intelligence (AI). These developments have led to the large-scale application of AI in our everyday lives and AI-research within healthcare. A potentially promising application of AI lies in imaging analysis. For example, within gastroenterology this means the detection and classification of colorectal polyps and Barrett's neoplasia, disease severity scoring of inflammatory bowel diseases, and differentiating pancreatic cancer from chronic pancreatitis.
Despite the investments in AI-research, there is a lack in knowledge concerning patients' and physicians' perspectives on AI in healthcare. This prospective questionnaire study investigates these perspectives, obtaining data from both gastroenterology (GI) patients and GI-physicians within the Netherlands. The questionnaires focus on the knowledge, experience, and opinion of AI, particularly concerning the implementation of AI in (gastroenterology) healthcare. Furthermore, the current (endoscopic) infrastructure within Dutch hospitals will be investigated for its readnessy for AI.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Limburg
-
Maastricht, Limburg, Niederlande, 6202AZ
- Maastricht University Medical Center
-
-
Noord-Brabant
-
Eindhoven, Noord-Brabant, Niederlande, 5623 EJ
- Catharina Ziekenhuis Eindhoven
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Gastroenterology patients who will have an outpatient appointment for an endoscopic procedure in the context of the national bowel cancer screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases, in one of two Dutch hospitals between April 2020 and September 2020.
Gastroenterologists and gastroenterology fellows working in Dutch hospitals.
Beschreibung
Inclusion Criteria:
- Gastrointestinal (GI) patients with an outpatient appointment in the gastroenterology department for an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases (in one of the two participating hospitals);
- Gastroenterologists working in Dutch hospitals;
- Gastroenterology fellows working in Dutch hospitals;
- Minimal age of 18 years old.
Exclusion Criteria:
- No appropriate understanding of the Dutch language;
- Not willing to sign informed consent;
- Objection to participate in medical scientific research, reported in the medical file.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Gastroenterology patients
Patient receiving an endoscopic procedure because of regular care will be considered eligible for inclusion. Patients receive an endoscopic procedure in the context of the Dutch national screening program, because of gastrointestinal symptoms, or because of follow-up of previously diagnosed bowel diseases. Patients will be asked to complete a questionnaire concerning AI. No intervention will be administered. |
Questionnaire concerning artificial intelligence and its implementation in healthcare.
GI patients and GI physicians will be provided with slightly different questionnaires.
|
Gastroenterology physicians
GI physicians (both gastroenterologists and gastroenterology fellows), participating in a yearly gastroenterology and hepatology training day, will be asked for their participation in this study. Physician will be asked to complete a questionnaire concerning AI. No intervention will be administered. |
Questionnaire concerning artificial intelligence and its implementation in healthcare.
GI patients and GI physicians will be provided with slightly different questionnaires.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The knowledge on AI investigated by means of a questionnaire
Zeitfenster: 6 months
|
The knowledge on AI in healthcare among gastroenterology patients and physicians, investigated by means of a questionnaire.
|
6 months
|
The experience with AI investigated by means of a questionnaire
Zeitfenster: 6 months
|
The experience with AI (in healthcare) among gastroenterology patients and physicians, investigated by means of a questionnaire.
|
6 months
|
The opinion on AI investigated by means of a questionnaire
Zeitfenster: 6 months
|
The oninion on AI in healthcare among gastroenterology patients and physicians, investigated by means of a questionnaire.
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Willingness of physicians to use AI in (gastroenterology) healthcare
Zeitfenster: 6 months
|
The willingness to apply AI in (gastroenterology) healthcare among gastroenterology physicians.
|
6 months
|
Willingness to apply AI in (gastroenterology) healthcare
Zeitfenster: 6 months
|
The willingness of gastroenterology patients for their physicians to apply AI in (gastroenterology) healthcare.
|
6 months
|
Advantages and disadvantages of AI use in (gastroenterology) healthcare
Zeitfenster: 6 months
|
Important advantages and disadvantages of AI use in (gastroenterology) healthcare among gastroenterology patients and physicians.
|
6 months
|
Potential domains within gastroenterology and hepatology for AI use
Zeitfenster: 6 months
|
Potential domains within gastroenterology and hepatology for AI use indicated by GI physicians.
|
6 months
|
Mandatory infrastructure for AI use in healthcare
Zeitfenster: 6 months
|
The availability of technical facilities and infrastructures within endoscopy to implement and apply AI in Dutch hospitals.
|
6 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Ad Masclee, Prof Dr MD, Maastricht Universitair Medisch Centrum
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smail-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020 Jan;158(1):76-94.e2. doi: 10.1053/j.gastro.2019.08.058. Epub 2019 Oct 5.
- Shaban-Nejad A, Michalowski M, Buckeridge DL. Health intelligence: how artificial intelligence transforms population and personalized health. NPJ Digit Med. 2018 Oct 2;1:53. doi: 10.1038/s41746-018-0058-9. eCollection 2018.
- Labovitz DL, Shafner L, Reyes Gil M, Virmani D, Hanina A. Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy. Stroke. 2017 May;48(5):1416-1419. doi: 10.1161/STROKEAHA.116.016281. Epub 2017 Apr 6.
- Waymel Q, Badr S, Demondion X, Cotten A, Jacques T. Impact of the rise of artificial intelligence in radiology: What do radiologists think? Diagn Interv Imaging. 2019 Jun;100(6):327-336. doi: 10.1016/j.diii.2019.03.015. Epub 2019 May 6.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- METC 2020-2281
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Gastrointestinale Störungen
-
Centre Hospitalier Universitaire DijonAbgeschlossen
-
Hospices Civils de LyonAbgeschlossenNeuromyelitis-Optica-Spektrum-Erkrankungen | Neuromyelitis optica Spectrum Related DisordersFrankreich
-
Assistance Publique Hopitaux De MarseilleAbgeschlossenGastro-Entero-Pankreas-Tumoren (GEPs)Frankreich
-
Istituto Scientifico Romagnolo per lo Studio e...Istituto Europeo di Oncologia IEO MILANOAktiv, nicht rekrutierendNeuroendokrine Tumoren | Gastro Entero Pankreatische Neuroendokrine TumorenItalien